Dr. Stephen Leroy Hooper, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 57 Abigail Ln, North East, MD 21901 Phone: 410-287-5863 |
News Archive
How is it that some people who apparently freeze to death, with no heart rate or respiration for extended periods, can be brought back to life with no long-term negative health consequences? New findings from the laboratory of cell biologist Mark B. Roth, Ph.D., of Fred Hutchinson Cancer Research Center, may help explain the mechanics behind this widely documented phenomenon.
Elorac, Inc., a rapidly growing specialty pharmaceutical company focused on the treatment of dermatological disorders, announced results of two Phase III studies of its patented Carbamide Peroxide (CPO) solution for the treatment of inflammatory acne vulgaris and rosacea at the Lazard Capital Markets 7th Annual Healthcare Conference in New York.
MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.
Arthritis affects more than half of adults with heart disease and appears to be a substantial barrier to utilizing physical activity to help manage their condition, according to a new Morbidity and Mortality Weekly Report (MMWR) study released by the Centers for Disease Control and Prevention (CDC).
› Verified 6 days ago